Details

Autor(en) / Beteiligte

• Guan, Y L
• Zhang, D Z
• Yang, Y X
• Wan, R J
• Tang, L Q
• Zeng, W Q
• Kang, Juan

Titel

The clinical value of von Willebrand factor and VITRO score in evaluating disease progression in patients with HBV infection

Ist Teil von

• Zhonghua gan zang bing za zhi, 2022-03, Vol.30 (3), p.309

Ort / Verlag

China

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• To explore the clinical value of von Willebrand Factor (vWF) and VITRO score (vWF:Ag/platelet count) in assessing disease progression in patients with HBV infection. Randomly collect relevant clinical data of 308 patients with HBV infection (including 154 cases of chronic hepatitis B, 66 cases of hepatitis B cirrhosis in compensatory period, 88 cases of hepatitis B cirrhosis in decompensated period) from December 1, 2018 to January 5, 2021 in the Second Affiliated Hospital of Chongqing Medical University. The vWF values are measured by a uniform optical method, and all data are included using a uniform standard. Analyze the difference and significance of plasma vWF level and VITRO score in chronic hepatitis B, hepatitis B cirrhosis in the compensatory phase and decompensated phase. The plasma vWF level and VITRO score of the chronic hepatitis B group were (139.47±76.44) and (0.86±0.8), respectively, and the hepatitis B cirrhosis compensated group was (164.95±67.12 and 1.44±1.14), respectively. Hepatitis cirrh